Alnylam Pharmaceuticals, Inc. (ALNY) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for Alnylam Pharmaceuticals, Inc., with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| P/E Ratio | 166.04x | -107.99x | -54.31x | -25.57x | -23.55x | -17.41x |
| P/B Ratio | 66.01x | 447.73x | -108.36x | -182.78x | 34.15x | 14.71x |
| P/S Ratio | 14.03x | 13.36x | 13.08x | 27.88x | 23.79x | 30.32x |
| Profitability | ||||||
| Gross Margin | 81.8% | 85.6% | 83.0% | 83.7% | 83.4% | 84.2% |
| Operating Margin | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% | -168.1% |
| Net Margin | 8.4% | -12.4% | -24.1% | -109.0% | -101.0% | -174.1% |
| EBITDA Margin | 15.0% | -8.0% | -14.1% | -89.3% | -78.4% | -149.4% |
| Liquidity | ||||||
| Current Ratio | 2.76x | 2.78x | 3.08x | 3.51x | 4.04x | 4.47x |
| Quick Ratio | 2.71x | 2.71x | 2.99x | 3.34x | 3.91x | 4.34x |
| Leverage | ||||||
| Debt/Equity | 1.62x | 40.89x | -5.92x | -8.34x | 1.70x | 0.51x |
YoY = year-over-year change. Source: FMP..